Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Bioavailability of Telmisartan/HCTZ Formulations
NCT02262572Phase 1Completed
- Sponsor
- Boehringer Ingelheim
- Start
- Apr 2003
- Primary completion
- Aug 2003
- Modality
- Small Molecules
01
Overview
Phase 1, randomised, open-label trial of telmisartan and hydrochlorothiazide in hypertension (HTN) (3 arms), sponsored by Boehringer Ingelheim. Primary endpoints: Area under the concentration-time curve of the analyte in plasma over the time interval from 0 extrapolated to infinity up to 72 hours, Maximum measured concentration of the analyte in plasma up to 72 hours and 1 more. Started Apr 2003; status: completed.
02
Drugs
telmisartanhydrochlorothiazide
03
Conditions
hypertension (HTN)
Beyond the preview
Go deeper on NCT02262572.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02262572.